The Relations Of Prognosis And Expression Of TKR In Triple-negative Breast Cancer

Objective:To study the expression of PTK receptor EGFR, IGF-1R and c-met in triple-negative breast cancer, and try to find the relationship with survival and prognosis of triple-negative breast cancer.Methods:53 triple-negative breast cancer (infitrating ductal carcinoma or lobular carcinoma) patients from Second Xiangya Hospital, Central South University since Dec 2003 to May 2010,are all female, age 33.8 to 60.1 (median age 44.5),45 infitrating ductal carcinomas while 8 infiltrating lobular carcinomas. StageⅠtoⅢ(stageⅠ12, stageⅡ32,stageⅢ9),fixed by 10% formalin, sliced after paraffin imbedding, HE staining. The expression of PTK receptor EGFR,IGF-1R and c-met was determined by immunohistochemistry(-and+for the low expression group,++and+++for high expression group). Log-rank test was used to statistical treatment, P<0.05 with statistic significance.Results: 1,The rate of expression of PTK receptor EGFR in triple-negative breast cancer is 37.7%(20/53), (-) accounted for 62.3%(33/53), (+) accounted for 9.4%(5/53), (++) accounted for 22.6%(12/ 53), (+++) accounted for 5.7%(3/53).The median survival time of 38 patients with low expression of EGFR is 53.2 months, the median survival time of 15 patients with high EGFR expression is 42.1 months. The difference between the two is clear statistic significance(χ2=5.32, p<0.05);2,The rate of expression of PTK receptor IGF-1R in triple-negative breast cancer is 73.6%(39/53), (-) accounted for 26.4%(14/53), (+) accounted for 17.0%(9/53), (++) accounted for 26.4%(14 /53), (+++) accounted for 30.2%(16/53).The median survival time of 23 patients with low expression of IGF-1R is 49.9 months, the median survival time of 30 patients with high IGF-1R expression is 40.5 months. The difference between the two is clear statistic significance (χ2=4.12,p<0.05);3,The rate of expression of PTK receptor c-met in triple-negative breast cancer is 83.0%(44/53), (-) accounted for 17.0%(9/53), (+) accounted for 9.4%(5/53), (++) accounted for 30.2%(16/53),(+++)accounted for 43.4%(23/53).The median survival time of 14 patients with low expression of c-met is 51.5 months, the median survival time of 39 patients with high c-met expression is 38.2 months. The difference between the two is clear statistic significance (χ2=6.25, p<0.05).Conclusion;EGFR, IGF-1R and c-met expression testing of triple-negative breast cancer tissue may help to prognosis forecast.